Madrigal Pharmaceuticals Inc (MDGL) USD0.00010
Sell:$334.59Buy:$335.40
$11.02
(3.40%)
0.87%- This stock can be held in a
Stocks and Shares ISA$11.02
(3.40%)$11.02
(3.40%)Company Information
About this company
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Key people
Key facts
- EPICMDGL
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS5588681057
- Market cap$7.31bn
- Employees528
- Shares in issue22.08m
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.